View Post

HRQoL effects of breast cancer prognosis, treatment predict mortality risk

In In The News by Barbara Jacoby

By: Hannah Kitt From: medwirenews.com The health-related quality of life (HRQoL) of patients with ductal carcinoma in situ (DCIS) or invasive breast cancer is impaired by their prognosis and treatment, and measuring the extent of impairment could help predict mortality risk, research suggests. Dale Sandler (National Institutes of Health, Research Triangle Park, North Carolina, USA) and co-investigators say: “The evaluation …

View Post

Ductal Carcinoma in Situ Associated With Higher Breast Cancer Death Risk

In Clinical Trials by Barbara Jacoby

By: Rose McNulty From: ajmc.com Findings suggest that current standard treatment does not eliminate the risk of breast cancer-specific death in the 20 years after DCIS diagnosis. Women with ductal carcinoma in situ (DCIS) were more than 3 times as likely to die of breast cancer than women without DCIS, a large cohort study published in JAMA Network Open found.1 …

View Post

George Mason University breast cancer treatment patent licensed by Targeted Pharmaceuticals

In Clinical Trials by Barbara Jacoby

Source: George Mason University From: eurekalert.org A patent granted to George Mason University Research Foundation Inc., which describes a novel treatment method for pre-invasive breast cancer, has been exclusively licensed to Targeted Pharmaceuticals LLC, a clinical-stage biopharmaceutical company focused on utilizing cannabinoids for the treatment of oncology and central nervous system disorders. The patent, secured by faculty members of George …

View Post

Vaccine may prevent progression of DCIS to breast cancer

In In The News by Barbara Jacoby

From: healio.com Researchers at Mayo Clinic received a $3.7 million grant from the U.S. Department of Defense to test a vaccine designed to establish lifelong immunity against the development of breast cancer in women with ductal carcinoma in situ. No methods exist to detect which of the 35% of ductal carcinoma in situ (DCIS) cases will progress to cancer if …

New test identifies aggressive form of breast cancer

In In The News by Barbara Jacoby

By: Kristen Jordan Shamus From: freep.com A University of Michigan researcher has invented a technology that can take some of the guesswork out of whether one form of early breast cancer is aggressive and likely to metastasize. Dr. Howard Petty, a cancer survivor himself, came up with an imaging technology called Biomarker Ratio Imaging Microscopy — or BRIM — that highlights …